Cwm, LLC Mannkind Corp Transaction History

Cwm, LLC

$33.3 Billion
Q3 2025

A detailed history of Cwm, LLC transactions in Mannkind Corp stock. As of the latest transaction made, Cwm, LLC holds 18,894 shares of MNKD stock, worth $103,728. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,894

Previous 543 3379.56%

Holding current value

$103,728

Previous $2,000 4950.0%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 15, 2025	BUY	$3.42 - $5.74 $62,760 - $105,334	18,351 Added 3379.56%	18,894 $101,000
Q2 2025 Jul 25, 2025	SELL	$3.71 - $5.04 $1,250 - $1,698	-337 Reduced 38.3%	543 $2,000
Q1 2025 May 01, 2025	BUY	$4.92 - $6.6 $806 - $1,082	164 Added 22.91%	880 $4,000
Q4 2024 Feb 04, 2025	SELL	$5.93 - $7.44 $1,500 - $1,882	-253 Reduced 26.11%	716 $5,000
Q3 2024 Oct 08, 2024	SELL	$5.01 - $6.7 $23,762 - $31,778	-4,743 Reduced 83.04%	969 $6,000
Q2 2024 Jul 09, 2024	BUY	$4.05 - $5.43 $1,077 - $1,444	266 Added 4.88%	5,712 $30,000
Q1 2024 Apr 05, 2024	BUY	$3.25 - $5.27 $58 - $94	18 Added 0.33%	5,446 $25,000
Q4 2023 Feb 01, 2024	BUY	$3.34 - $4.29 $16,700 - $21,450	5,000 Added 1168.22%	5,428 $20,000
Q3 2023 Oct 11, 2023	BUY	$3.91 - $5.45 $1,673 - $2,332	428 New	428 $2,000
Q2 2022 Jul 28, 2022	SELL	$2.67 - $4.77 $24 - $42	-9 Reduced 31.03%	20 $0
Q4 2021 Jan 31, 2022	SELL	$4.05 - $5.37 $4,025 - $5,337	-994 Reduced 97.17%	29 $0
Q2 2020 Jul 22, 2020	SELL	$0.94 - $2.21 $6,855 - $16,117	-7,293 Reduced 87.7%	1,023 $2,000
Q1 2019 Apr 22, 2019	SELL	$1.14 - $2.25 $683 - $1,350	-600 Reduced 6.73%	8,316 $16,000
Q4 2018 Jan 25, 2019	BUY	$1.02 - $2.05 $612 - $1,230	600 Added 7.22%	8,916 $9,000
Q3 2018 Oct 29, 2018	BUY	$1.01 - $2.19 $8,399 - $18,212	8,316 New	8,316 $15,000

Others Institutions Holding MNKD

# of Institutions

251

Shares Held

161M

Call Options Held

1.24M

Put Options Held

183K

View Full List

About MANNKIND CORP

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.41B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

More about MNKD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account